Browse Biological products industry topic

Health aspects subtopic

Articles 1-100 out of 100 article(s) Title Author Type Date Words Genta to Support Initiation of New Clinical Trial using Ganite[R] as Treatment for Life-Threatening Infections in Patients with Cystic Fibrosis. Dec 2, 2009 1007 BioInvent Signs Licensing Agreement with Daiichi Sankyo for the Discovery and Development of Therapeutic Antibodies. Nov 13, 2009 510 United States : European panel reviewing infections linked to Tysabri. Oct 26, 2009 273 New BioTime Subsidiary, OncoCyte Corporation, Receives $2 Million Equity Financing to Develop Cancer Treatments Using Stem Cell Technology. Oct 15, 2009 737 United States: AVI BioPharma gets $11.5M military contract. Oct 6, 2009 262 Aphios Awarded NIH ARRA Challenge Grant for Pathogen Inactivation Technology for Blood Products. Sep 30, 2009 549 European Commission Grants Conditional Marketing Authorization to Cayston[R] (Aztreonam Lysine) for the Treatment of Chronic Pulmonary Infections Due to Pseudomonas Aeruginosa in Patients with Cystic Fibrosis. Sep 23, 2009 1516 Enzo Biochem and National Institutes of Health to Cooperate in Development of Enzo's Novel Therapeutic Candidate for Treatment of Autoimmune Uveitis. Sep 21, 2009 974 FAB Pharma, a Biopharma Company Developing Drugs to Treat Severe Bacterial Infections, Raises [euro]2.3 Million in Series A Funding and Begins Recruitment for a Phase I Trial of Its Lead Compound. Sep 12, 2009 431 Statement by Dr. Anthony Fauci, Director, National Institute of Allergy and Infections Diseases, NIH, Regarding Early Results from Clinical Trials of 2009 H1N1 Influenza Vaccines in Healthy Adults. Sep 11, 2009 736 Vitro's Cancer Stem Cell Therapy Complements New Hedge Hog Drugs. Sep 10, 2009 796 United States : Vitro Builds Its Product and Technology Base for Cancer Stem Cell Therapy. Sep 2, 2009 381 Vitro Builds Its Product and Technology Base for Cancer Stem Cell Therapy. Sep 1, 2009 707 Aphios Awarded NIH Grant for CFI Virus and Pathogen Inactivation Technology for Blood Products and Biologics. Aug 4, 2009 511 Seattle Genetics Initiates Phase II Trial of SGN-35 for Anaplastic Large Cell Lymphoma. Jun 18, 2009 862 StemCells, Inc. Announces Positive Phase I Batten Trial Results. Jun 8, 2009 2470 Genentech Announces Full Results from First Phase III Study of Avastin in Early-Stage Colon Cancer. May 30, 2009 1676 BioTime Awarded a $4.7 Million Research Grant from the California Institute for Regenerative Medicine. Apr 30, 2009 1490 Experts Available to Discuss: US Responding as If Swine Flu Will Be Pandemic. Apr 28, 2009 917 Merck & Co., Inc., Medarex, Inc. and Massachusetts Biologic Laboratories Sign Exclusive Licensing Agreement for Investigational Monoclonal Antibody Combination for Clostridium Difficile Infection. Apr 21, 2009 1663 Reportlinker Adds World Cancer Therapies Market Report. Apr 1, 2009 3280 National Cancer Institute (NCI) Contracts with Aphios to Develop Nanotech Combination Therapy for Certain Cancers. Mar 31, 2009 475 Stratatech Engineers Skin Substitute with Potent Anti-Infective Function. Feb 3, 2009 781 Profectus BioSciences Awarded $21.6 Million in NIH Contracts to Develop a HIV Preventative and a HIV Therapeutic Vaccine. Dec 8, 2008 584 Acorda Therapeutics to Present an Overview of its Preclinical Pipeline at Windhover Therapeutic Area Partnerships Conference. Conference news Nov 3, 2008 468 Gilead Announces Two-Year Data from Pivotal Phase III Studies Evaluating Viread(R) for Chronic Hepatitis B. Nov 1, 2008 2877 Genentech, GlycArt and Roche Enter into Collaboration Agreement for Potential Cancer Therapy. Oct 3, 2008 751 StemCells, Inc. Receives NIH Grant to Pursue Cell-Based Therapeutic for Hepatitis C. Oct 2, 2008 904 BioTime, Inc.'s Subsidiary, Embryome Sciences, Inc., Licenses Virus-Free iPS and Embryonic Stem Cell Differentiation Technology. Aug 21, 2008 1249 U.S. Food and Drug Administration Approves Viread(R) for Chronic Hepatitis B in Adults. Aug 11, 2008 1560 Therapeutic DNA Vaccine Company Inovio Biomedical Presenting at BIO International. Jun 17, 2008 538 Second Phase III Study of Avastin Plus Chemotherapy Shows Improved Progression-Free Survival in Women with Advanced HER2-Negative Breast Cancer. May 31, 2008 1320 Cell Genesys Reports Encouraging Interim Data From Phase 1 Clinical Trial of CG0070 in Recurrent Bladder Cancer. May 21, 2008 1042 Therapeutic DNA Vaccine Company Inovio Biomedical to Present at Upcoming Scientific Conferences. Conference news May 20, 2008 485 United States: AVI BioPharma Announces Significant Advance in the Potential Treatment of Ebola and Marburg Virus Infections. May 14, 2008 355 ImmuneRegen(R) BioSciences to Provide Adjuvant to DynPort Vaccine Company for Development of an Inactivated Vaccine against Venezuelan Equine Encephalitis Virus. Apr 30, 2008 931 Gilead Announces 72-Week Data From Two Pivotal Phase III Studies Evaluating Viread(R) for the Treatment of Chronic Hepatitis B. Apr 24, 2008 2878 Pfizer and AVANT Enter into Licensing and Development Agreement for Novel Therapeutic Vaccine Candidate for Brain Cancer. Apr 16, 2008 1701 Therapeutic Vaccine Company Inovio Biomedical Demonstrates Utility of Its Electroporation Delivery Technology as Potent Vaccine Adjuvant. Apr 9, 2008 976 PanGenetics Raises 23 Million Euro in Series C Financing to Fund Clinical Advancement of Its Therapeutic Antibody Programs. Mar 5, 2008 1166 Inhibitex HIV Integrase Inhibitor Data Presented at 15th Annual Conference on Retroviruses and Opportunistic Infections. Conference news Feb 7, 2008 749 Therapeutic DNA Vaccine Company, Inovio Biomedical, Promotes Punit Dhillon to Vice President of Finance & Operations. Jan 30, 2008 676 Therapeutic DNA Vaccine Company Inovio Biomedical Corp. Announces 'Clinical Trials Update' Conference Call on Jan. 29. Jan 24, 2008 599 Bristol-Myers Squibb and Gilead Sciences Expand Their Alliance to Include Commercialization of ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) in Europe. Dec 11, 2007 2101 AVI BioPharma to Present on NEUGENE Countermeasures to Biological Threats at U.S. Department of Defense 2007 Biodefense Research Conference. Conference news Nov 6, 2007 975 Gilead Announces 48-Week Data from Two Pivotal Phase III Studies Evaluating Viread(R) For the Treatment of Chronic Hepatitis B. Nov 2, 2007 2612 NIH AWARDS PHARMATHENE UP TO $13.9 MIL FOR ANTHRAX ANTI-TOXIN. Nov 1, 2007 1132 Epidemiologic and virologic investigation of hand, foot, and mouth disease, southern Vietnam, 2005. Van Tu, Phan; Thao, Nguyen Thi Thanh; Perera, David; Huu, Truong Khanh; Tien, Nguyen Thi Kim; Thuong Nov 1, 2007 5777 Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV. Oct 17, 2007 2168 AVI BioPharma Receives Department of Defense Contract for NEUGENE Program in Dengue Virus. Sep 19, 2007 623 Data on death in Targeted Genetics drug test to be aired. Sep 14, 2007 674 AVI BioPharma Drug Demonstrates Strong Survival Benefits and Elimination of Ebola Virus in Animals. Sep 12, 2007 938 Windhover Information Announces Its List of Top 10 Licensable Projects in the Hottest Therapeutic Areas. Sep 12, 2007 823 Second test for screening organs, blood for WNV approved by FDA. Sep 1, 2007 516 Fungus infection killed patient; Targeted Genetics' clinical trial; Role of injection is still uncertain. Aug 18, 2007 639 Foot and mouth: we must keep vigilant. Aug 8, 2007 370 AVI BioPharma Partner Global Therapeutics Announces Positive Pre-Clinical Results Shown Using NEUGENE Antisense Drug in Prevention of Cardiovascular Restenosis. Financial report Jul 25, 2007 830 Second Phase III Study Evaluating Gilead's Viread(R) for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint. Jun 25, 2007 1680 Phase III Study Evaluating Gilead's Viread(R) for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint. Jun 6, 2007 1741 AVI BioPharma Receives DoD Contracts for Bioterrorism Response Therapies. May 7, 2007 1139 New Report Illuminates Ampligen(R)'s Unique Mechanism of Action. Apr 30, 2007 995 Japanese Ministry Awards Grant to Advance Studies with Influenza Vaccines Co-Administered with Hemispherx's Ampligen(R). Apr 12, 2007 680 FermaVir Pharmaceuticals, Inc. Signs Definitive Agreement to Be Acquired by Inhibitex, Inc. Apr 10, 2007 1299 Inhibitex Signs Definitive Agreement to Acquire FermaVir Pharmaceuticals. Apr 10, 2007 1957 Enzo Therapeutics Treats First Patient in Phase I/II Study of Antisense Gene Therapy for HIV-1 Infections. Mar 13, 2007 972 David H. Murdock - Investing in Therapeutic Vaccine Company. Mar 9, 2007 437 Cerus Corporation Awarded Grants for Its Listeria-Based Vaccine Platforms. Mar 5, 2007 738 AVI BioPharma Presents Novel HIV Drug Candidate Results. Mar 1, 2007 410 AVAX Technologies Announces Collaboration with Cancer Treatment Centers of America. Feb 21, 2007 1197 Seattle Genetics and Agensys Announce Collaboration to Co-Develop and Commercialize Antibody-Drug Conjugate Therapies for Cancer. Jan 8, 2007 955 ZLB Behring Completes Purchase of CytoGam(R) Immunoglobulin Therapy From MedImmune. Company overview Dec 18, 2006 474 AVI BioPharma Publishes Preclinical Data Showing NEUGENE Antisense Inhibition of Multiple Strains of Influenza A Virus. Oct 27, 2006 895 AVI BioPharma Initiates NEUGENE Antisense Clinical Program in Coronary Artery Bypass Grafting. Clinical report Oct 18, 2006 948 AVI BioPharma Reports Results on Hepatitis C Virus Clinical Trial. Oct 4, 2006 1023 AVI BioPharma Presents Positive Preclinical Data Evaluating NEUGENE Antisense Compounds Against Influenza A Virus and the E. coli Bacteria. Sep 29, 2006 495 Biogen Idec and Alnylam Form Alliance to Discover and Develop Therapeutics for the Potential Treatment of Progressive Multifocal Leukoencephalopathy (PML); Collaboration to Focus on RNAi Therapeutics Targeting the JC Virus. Sep 20, 2006 1285 Hemispherx Biopharma to Present at The First International Conference on Avian Influenza in Humans at the Pasteur Institute; Novel Therapeutic Approach Attacks Virus at 3 Levels Simultaneously. Jun 27, 2006 823 New Data Show FUZEON(R) Continues to Provide Significant Immune System Benefits in Patients Despite Ongoing Viral Replication. Jun 26, 2006 1591 Celera Genomics and Medarex Establish Therapeutic Antibody Collaboration in Cancer; Collaboration Combines Celera's Protein Discoveries with Medarex's Expertise in Developing Fully Human Antibody Therapeutics. Jun 22, 2006 1304 Interim Data on Use of tgAAC94 in the Treatment of Inflammatory Arthritis Presented at the European Rheumatology Meeting; Results Provide Preliminary Evidence for Sustained Improvement in Signs and Symptoms of Disease. Jun 22, 2006 1208 AVI BioPharma to Present at Rodman & Renshaw 3rd Annual Security, Biodefense & Connectivity Investor Conference. Jun 19, 2006 369 Targeted Genetics and Collaborators Advance Key Technologies For AAV-Based Product Development. Jun 5, 2006 1060 Targeted Genetics Enhances Inflammatory Arthritis Product Development Platform. Jun 5, 2006 799 Targeted Genetics Presents Encouraging Interim Data From an Ongoing Phase I/II Trial of tgAAC94 in Patients with Inflammatory Arthritis. Jun 1, 2006 1411 Amgen Oncology Highlights Upcoming Data Presentations at the American Society of Clinical Oncology Annual Meeting; Clinical Data to be Presented on Four Investigational Targeted Cancer Therapies. May 31, 2006 1615 Progenics Broadens Collaboration with Seattle Genetics for Prostate Cancer Therapy; Positive Preclinical Findings on PSMA Antibody-Drug Conjugate Published in Clinical Cancer Research Journal. May 25, 2006 1137 AVI BioPharma Presents Initial Results on Hepatitis C Virus Clinical Trial at the International Conference on Antiviral Research Annual Meeting. May 10, 2006 1180 AVI BioPharma Provides Update on Hepatitis C Virus Clinical Trial Status; Data from the Phase I/II Accepted for Oral Platform Presentation at ICAR. Apr 20, 2006 860 BioInvent and Immusol to Collaborate on Antibody Therapeutic for Macular Degeneration. Apr 3, 2006 613 AVI BioPharma Reports Successful Inhibition of Multiple Subtypes of Influenza A Using NEUGENE Antisense Therapeutic. Mar 30, 2006 689 AVI BioPharma's NEUGENE Shows Success Against Deadly Ebola Virus; Results Published in Online Journal Public Library of Science (PLoS) Pathogens. Jan 13, 2006 699 AVI BioPharma Reports Favorable Safety and Pharmacokinetic Data From Its Clinical Trial Targeting Hepatitis C Virus; NEUGENE Antisense Compound Was Well-Tolerated and Exhibited Favorable Pharmacokinetic Parameters. Jan 10, 2006 1038 Chiron Foundation Awards Grants to Seven Organizations Committed to Fighting Global Health Threats. Jan 5, 2006 1030 Increased Defense-Related Funding of AVI BioPharma Approved; $11 Million Allocated for Development of Therapeutics for Ebola, Marburg and Dengue Viruses, and for Countermeasures for Anthrax and Ricin Toxins. Jan 4, 2006 1109 New Congressional Defense Bill Supports Development and Purchase of Vaccines to Meet the Nation's Public Health Threats; AVANT Expects to Participate in the Development of New Vaccine Technologies to Meet These Threats. Dec 22, 2005 738 MethylGene Unveils HDAC Anti-Fungal Program. Dec 16, 2005 674 Data Show Efficacy of Standard Dosing Regimen of AmBisome(R) is Similar to High Loading Dose for Patients with Invasive Fungal Infections. Dec 12, 2005 1306 Hemispherx Biopharma Enters Research Agreement with Defence R&D Canada. Nov 29, 2005 950 Preliminary 24-Week Data Evaluating the Impact of Switching from Twice-Daily Combivir(R) to Once-Daily Truvada(R) in Patients with HIV Presented at 10th European AIDS Conference. Nov 17, 2005 1829 Studies Continue to Highlight Hemispherx's Ampligen(R) as Broadly Effective Adjuvant to Avian Influenza Treatments; Ampligen(R) Demonstrates Strong Therapeutic Synergy with Relenza(R). Nov 3, 2005 763